Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 18/20 | 0.72 |
| ▸ | RARB | P10826 | 16/20 | 0.72 |
| ▸ | RARA | P10276 | 15/20 | 0.72 |
| ▸ | RXRA | P19793 | 14/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.72 |
| ▸ | GMNN | O75496 | 1/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | THPO | P40225 | 1/20 | 0.72 |
| ▸ | MTOR | P42345 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Temarotene SCHEMBL7544424 | 0.93 | RARG (0.77) | RARGRARBRARARXRAKDM4E | |
| Temarotene SCHEMBL455747 | 0.93 | RARG (0.77) | RARGRARBRARARXRAKDM4E | |
| Temarotene SCHEMBL29363514 | 0.93 | RARG (0.77) | RARGRARBRARARXRAKDM4E | |
| Temarotene SCHEMBL5999341 | 0.93 | RARG (0.77) | RARGRARBRARARXRAKDM4E | |
| Temarotene SCHEMBL10723294 | 0.89 | RARG (0.71) | RARGRARBRARARXRAKDM4E | |
| Sumarotene SCHEMBL449752 | 0.86 | RARG (0.70) | RARGRARBRARARXRAKDM4E | |
| Sumarotene SCHEMBL7062910 | 0.86 | RARG (0.70) | RARGRARBRARARXRAKDM4E | |
| Tamibarotene SCHEMBL21110862 | 0.85 | RARB (0.67) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL9859887 | 0.85 | RARG (0.74) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL8776376 | 0.85 | RARG (0.74) | RARGRARBRARARXRAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009333-A1 | PHARMACEUTICAL OR COSMETIC COMPOSITION AND USE OF A PKC INHIBITOR WITH AN MMP INHIBITOR FOR INHIBITING LANGERHANS' CELL MIGRATION | LABORATORIES EXPANSCIENCE | 2011-01-13 | — | — | US | claimed |
| US-20080221017-A1 | Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting langerhans cell migration | LABORATOIRES EXPANSCIENCE | 2008-09-11 | — | — | US | claimed |
| EP-3151863-B1 | HYDROALCOHOLIC SYSTEM FOR NAIL TREATMENT | UNIV SANTIAGO COMPOSTELA (ES) | 2020-08-12 | — | — | EP | disclosed |
| US-20170224669-A1 | HYDROALCOHOLIC SYSTEM FOR NAIL TREATMENT | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2017-08-10 | — | — | US | disclosed |
| EP-3151863-A1 | HYDROALCOHOLIC SYSTEM FOR NAIL TREATMENT | Universidade De Santiago De Compostela (ES) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015185647-A1 | HYDROALCOHOLIC SYSTEM FOR NAIL TREATMENT | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2015-12-10 | — | — | WO | disclosed |
| EP-2952208-A1 | Hydroalcoholic system for nail treatment | Universidade de Santiago de Compostela (ES) | 2015-12-09 | — | — | EP | disclosed |
| US-8877261-B2 | Anti-redness active agent and cosmetic compositions comprising same | LABORATOIRES EXPANSCIENCE (FR) | 2014-11-04 | — | — | US | disclosed |
| US-8653117-B2 | Composition comprising at least one oxazoline to inhibit migration of langerhans cells, and uses thereof | LABORATOIRES EXPANSCIENCE (FR) | 2014-02-18 | — | — | US | disclosed |
| CN-101313057-B | Process for obtaining a triglyceride-rich refined avocado oil, and oil which can be obtained by means of such a process | EXPANSCIENCE LAB | 2013-08-21 | — | — | CN | disclosed |
| US-20130177662-A1 | NOVEL ANTI-REDNESS ACTIVE AGENT AND COSMETIC COMPOSITIONS COMPRISING SAME | LABORATOIRES EXPANSCIENCE | 2013-07-11 | — | — | US | disclosed |
| US-20090137453-A1 | COMPOSITION COMPRISING AT LEAST ONE OXAZOLINE TO INHIBIT MIGRATION OF LANGERHANS CELLS, AND USES THEREOF | MSIKA PHILIPPE | 2009-05-28 | — | — | US | disclosed |
| US-7511010-B2 | Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting Langerhans' cell migration | LABORATOIRES EXPANSCIENCE (FR) | 2009-03-31 | — | — | US | disclosed |
| CN-101313057-A | Process for obtaining a triglyceride-rich refined avocado oil, and oil which can be obtained by means of such a process | EXPANSCIENCE LAB (FR) | 2008-11-26 | — | — | CN | disclosed |
| US-20080221017-A1 | Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting langerhans cell migration | LABORATOIRES EXPANSCIENCE | 2008-09-11 | — | — | US | disclosed |
| US-20070116812-A1 | Process for producing refined avacado oil rich in triglycerides, and oil obtainable by said process | PHILIPPE MSIKA (FR) | 2007-05-24 | — | — | US | disclosed |
| US-20060194881-A1 | Composition comprising at least one alkanolamide to inhibit megration of langerhans cells and uses therof | MSIKA PHILIPPE | 2006-08-31 | — | — | US | disclosed |
| US-20050075380-A1 | Composition comprising at least one oxazolin for inhibiting langerhans cell migratio, and uses thereof | LABORATOIRES EXPANSCIENCE (FR) | 2005-04-07 | — | — | US | disclosed |
| US-20050075397-A1 | Composition comprising at least one alkanolamide for inhibiting langerhans cells migration, and uses thereof | LABORATOIRES EXPANSCIENCE (FR) | 2005-04-07 | — | — | US | disclosed |
| US-20040067910-A1 | Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans' cell migration | LABORATOIRES EXPANSCIENCE (FR) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075397-A1 | Composition comprising at least one alkanolamide for inhibiting langerhans cells migration, and uses thereof | ARG1, CPA3, MIF | RARG 784/4885RARB 1168/4885RARA 928/4885 |
| US-20090137453-A1 | COMPOSITION COMPRISING AT LEAST ONE OXAZOLINE TO INHIBIT MIGRATION OF LANGERHANS CELLS, AND USES THEREOF | ARG1, MIF, ZAP70 | RARG 1398/4885RARB 1578/4885RARA 1541/4885 |
| US-20040067910-A1 | Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans' cell migration | MMP1, MMP2, MMP13 | RARG 1419/4885RARB 1689/4885RARA 2262/4885 |
| US-20050075380-A1 | Composition comprising at least one oxazolin for inhibiting langerhans cell migratio, and uses thereof | MIF, CUTA, ARG1 | RARG 935/4885RARB 1308/4885RARA 974/4885 |
| US-20060194881-A1 | Composition comprising at least one alkanolamide to inhibit megration of langerhans cells and uses therof | TPSG1, CPA3, CTSF | RARG 1754/4885RARB 2159/4885RARA 1918/4885 |
| US-20080221017-A1 | Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting langerhans cell migration | MMP1, MMP13, MMP2 | RARG 1397/4885RARB 1695/4885RARA 2246/4885 |
| US-20110009333-A1 | PHARMACEUTICAL OR COSMETIC COMPOSITION AND USE OF A PKC INHIBITOR WITH AN MMP INHIBITOR FOR INHIBITING LANGERHANS' CELL MIGRATION | MMP1, MMP13, MMP2 | RARG 28/4885RARB 25/4885RARA 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.